



Date: 15th May, 2026

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Investors/ Analysts Presentation for the year ended on 31st March, 2026

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith Investors/ Analysts presentation for the year ended on 31st March, 2026.

The presentation shall also be made available at Company's website www.accretionpharma.com.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary and Compliance Officer

Encl.: As above



Accretion

Pharmaceuticals Limited

Investor Presentation May 2026



Disclaimer

This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Pharmaceuticals Limited (APL) and its group companies’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

Prior to November 29th, 2023, Accretion Pharmaceuticals Limited operated on the status of Partnership Firm and was converted into unlisted Public Limited Company on 29th November 2023. Accordingly, certain ledger balances pertaining to periods prior to the conversion have been suitably adjusted/reclassified. These factors include, but are not limited to, general market, macro-economic, government and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Accretion Pharmaceuticals Limited undertakes no obligation to periodically revise any forward-looking statements to reflect future/likely events or circumstances.

Table of Content



Company Overview



Business Overview



Industry Overview



Financial Highlights



Way Ahead




your text

Company Overview



Accretion at a glance



Leading manufacturer of high-quality pharmaceutical formulations and contract development manufacturing organization

- Emerged as a dynamic player in India's pharmaceutical landscape since its inception in 2012
- Incorporated in 29th November 2023

Experienced Management Team

- Significant experience in Pharmaceuticals Industry
- Long term vision and proven ability to achieve long term goals for Company

Modern manufacturing facility

- Headquartered in Ahmedabad, Gujarat
- Total installed capacity:- 1635 Mn
 - **Tablets – 1000 Mn**
 - **Oral Powder(Bottles & Pouch) – 153.75 Mn**
 - **Capsule – 450 Mn**
 - **Oral Liquid (Bottles) – 21.75 Mn**
 - **External Preparations (Tubes) - 9 Mn**

Certifications

- WHO- cGMP, GLP, Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP, ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018

Diversified Portfolio

- Specializing in high-quality generic and branded formulations, including tablets, capsules, oral liquids, oral powders, and external preparations

Strong financial performance

- 56.21% YoY growth in Revenues FY26
- Over 20.78% ROCE in FY26
- Conservation Balance sheet – Net Debt to Equity is 0.15 in FY26

Strong geographical presence

- Over 30+ countries across Africa, Southeast Asia, and Latin America



Mission

Our mission is to deliver state-of-the-art pharmaceutical manufacturing solutions that exceed client expectations. We are committed to combating diseases and advancing global health through innovative, high-quality medicines offered at competitive prices, striving towards a world free of ailments.

Vision

With our avant-garde, technologically advanced, and scalable manufacturing unit, our vision is to make a vital contribution to medicine manufacturing by harnessing our potential to achieve optimal results. We strive to be the leading partner in pharmaceutical development and manufacturing, renowned for our innovation, reliability, and commitment to quality.

An Emerging Indian CDMO Player with a growing Domestic Presence And Expanding Global Footprint

Journey So Far

2023

- Obtained ISO Certification 9001:2015, ISO Certification 14001:2015 and ISO Certification 22000:2018 from the ICV Assessments Private Limited
- Incorporation of “Accretion Pharmaceuticals Limited” as a Public Limited Company
- WHO-cGMP (current Good Manufacturing Practices) certification was received, granting the company cGMP approval from the World Health Organization (WHO)

2020


Received Indian Achievers Award for Emerging Company in Recognition of Outstanding Professional Achievements & Contribution in Nation Building

2012

Formed as a Partnership Firm in the name and style of “M/s Accretion pharmaceuticals

- Listed on the National Stock Exchange (NSE) SME Platform in mid-May 2025
- Received cGMP (Current Good Manufacturing Practices) approval from regulatory authorities of Malawi & Nigeria for its manufacturing facility

2025 - 26



Experienced Management Team

Mr. Vivek Ashok Kumar Patel



Promoter and Managing Director

- Bachelor's degree in Pharmacy from Gujarat University and an MBA in Pharma from DY Patil Institute
- Hands-on industry exposure during training at Alive Pharma
- Worked at Merck Limited, gaining insights into marketing logistics, and finance
- 15+ years of diversified expertise in both production and marketing within pharmaceutical industry

Mr. Harshad Nanubhai Rathod



Promoter, Executive Director & CFO

- Bachelor's degree in Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal
- 15+ years of experience in the pharmaceutical industry
- Former Marketing Head – Recspeed Healthcare with proven expertise in identifying growth opportunities
- Expertise in growth strategy & market expansion

Mr. Hardik Mukundbhai Prajapati



Promoter and Executive Director

- Master's in Pharmacy from Gujarat Technological University
- Strong industry foundation built at Lincoln Pharmaceuticals Limited
- Co-founder of Recspeed Healthcare, expanding presence across Gujarat
- Brings 15+ years of expertise in pharmaceutical production

Mr. Mayur Popatlal Sojitra



Promoter and Executive Director

- Bachelor's degree in Pharmacy from Gujarat University and MBA in International Business from University of Greenwich London
- 13+ years of experience in the pharmaceutical industry
- Embodies strategic excellence with a global perspective

Ms. Roshani Shah



Company Secretary & Compliance Officer

- CS, MBA in Finance and LLB from Gujarat University
- Over 9+ years of post-qualification experience in listed companies
- Expertise lies in corporate governance, regulatory compliance under SEBI regulations, the Companies Act, and Listing Regulations

Key Strengths

Visionary Leadership

- Over decade of experience in this business supported by team of professionals having knowledge of our various business functions

Integrated Business Model

- Our multifaceted model offers agility and resilience needed to navigate dynamic market demands
- Integrated approach enables us to consistently deliver precision, quality and value to our partners and customers

Diverse And Innovative Product Portfolio

- Our comprehensive portfolio positions us distinctively within a competitive landscape
- Continuous innovation and targeted portfolio expansion provide a sustained competitive advantage over competitors with narrower product focuses

State-of-the-art Manufacturing

- Our Ahmedabad facility showcases our commitment to quality, safety, and environmental stewardship, while its robust manufacturing capabilities ensure consistent, high-quality pharmaceutical production at scale



Strong Relationships

- Long-standing relationships with clients and suppliers fostering loyalty and industry reputation
- Collects feedback to enhance offerings, delivering high-quality products and responsive service for optimal customer satisfaction

Robust Global Presence

- With a robust presence in India and exports spanning over 30+ countries, including Africa, Southeast Asia, and Latin America

Consistent Financial Growth

- Strong financial performance with steady revenue growth, healthy margins, and robust returns, reflecting efficient capital use and positioning us for long-term success

your text


Business Overview



Our Comprehensive Therapeutic Offerings

Product by Dosage Forms

- Tablets
- Capsules
- Oral Liquids
- External Preparations
- Oral Powder



Therapeutic Segments


- Anti Malarial
- Antifungal & Anti Bacterial
- Anti Inflammatory
- Antihistamine
- Antiallergics
- Antibiotic
- Antitussives
- Anticold
- Antiulcer
- Antacid
- Anti-Diabetic Cardiac
- Anti-Hypertensive
- Psychotropic
- Vitamins and Supplement
- Antipruritic
- Antiseptic
- Antiparasitic
- Antiemetic
- Laxative

Dosage Forms - Tablets


-  Antibiotic
-  Antibacterial
-  Antifungal
-  Anti- Inflammatory
-  Antihistamine
-  Antiallergics
-  Antitussives
-  Anticold
-  Antiulcer and Antacid
-  Anti-Diabetic
-  Cardiac and Anti-Hypertensive
-  Psychotropic
-  Vitamins and Supplement



Revenue Contribution (Rs. In Crore)



Capacity and Capacity Utilization (In Crore)




Dosage Forms - Capsules


-  Antibacterial
-  Antifungal
-  Anti- Inflammatory
-  Antiulcer and Antacid
-  Cardiac and Anti-Hypertensive
-  Vitamins and Supplement



Revenue Contribution (Rs. In Crore)



Capacity and Capacity Utilization (In Crore)




Dosage Forms – Oral Liquids


-  Antibiotic
-  Antibacterial
-  Antifungal
-  Antihistamine
-  Antiallergics
-  Antitussives
-  Anticold
-  Antiulcer and Antacid
-  Vitamins and Supplement
-  Antiparasitic
-  Antiemetic
-  Laxative










Revenue Contribution (Rs. In Crore)



Capacity and Capacity Utilization (In Crore)




Dosage Forms – External Preparations


-  Antibiotic
-  Antibacterial
-  Antifungal
-  Anti-Inflammatory
-  Antipruritic
-  Antiulcer
-  Antiseptic












Revenue Contribution (Rs. In Crore)



Capacity and Capacity Utilization (In Crore)




Dosage Forms – Oral Powders


-  Antibiotic
-  Antibacterial
-  Antifungal
-  Antihistamine
-  Antiallergics
-  Antitussives
-  Anticold
-  Antiulcer and Antacid
-  Vitamins and Supplement



Revenue Contribution (Rs. In Crore)



Capacity and Capacity Utilization (In Crores)



...With state of art **manufacturing facility**



Manufacturing facility



Granulation



Liquid Filling & Sealing



Tableting Machine



Micro lab




QC lab



QC lab HPLC

Plant	Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat				
Dosage	Tablet	Capsules	Oral Liquid	Oral Powder	External Preparations
Regulatory Approvals	WHO cGMP, GLP & ISO 9001:2015, ISO 14001:2015, ISO 22000:2018 Certified				
Installed Capacity	1000 Mn	450 Mn	21.75 Mn (Bottles)	153.75 Mn (Bottles & Pouch)	9 Mn (Tubes)
Total Installed Capacity – 1635 Million					

...Creating Strong Global Presence since 2012




International

- Direct network across 30 countries
 - ✓ Africa, Southeast Asia, and Latin America
 - ✓ Countries exported through Merchant Exporters include Congo, Libya, Angola, Botswana, Venezuela and Cambodia
 - ✓ More than 70 merchant exporters

Domestic

- Domestic presence in more than 16 states across India
 - ✓ Gujarat, Maharashtra, Chhattisgarh, Assam, Karnataka, Uttar Pradesh, Madhya Pradesh, Bihar, Tamil Nadu, Andhra Pradesh, Odisha, Haryana, Delhi, Rajasthan, Telangana and Lakshadweep

Reward & Recognition



30th Sep, 2020 Mr. Harshad Rathod
 Director
 Accretion Pharmaceuticals
 Dear Mr. Harshad,
Congratulations on winning "Indian Achievers" Award for Emerging Company, 2020!
 You truly deserved this honour for your achievements and social contributions. I am sure this will motivate you to further excel in your field and inspire others as well. The achievement of this recognition is well-deserved in the prime hour writing of the occurrence of the award ceremony.
 Please find herewith the digital Certificate of Appreciation.
 The winning Trophy will be dispatched at your given communication address shortly. Also enclosed herewith the Indian Achievers' Award Logo which you can use for your PR, branding purpose in social media, website, brochures etc.
 Our team will contact to you soon for other deliverables.
 Thank you for being a part of Indian Achievers' Forum and its network. We will keep you posted on different updates regularly.
 We will love to have your valuable suggestions and feedback.
 With best wishes for many more achievements.

Harish Chandra
 Executive Director & Editor
 Indian Achievers' Forum & Achievers' World
 End: Certificate, Award Logo, IAF Logo

your text

Industry



Overview



India : Pharmacy of the World

The Indian Pharma industry is the world's **3rd largest by volume** and 14th by value



FY 2024-25 turnover: **Rs. 2,26,000 Cr**, growth in volume of 0.4% and 8.4% value growth

Largest supplier of generic drugs accounting for **20% of global supply**




Manufactures **60,000 generic brands**, across **60 therapeutic categories**

India **biggest suppliers of low-cost vaccines** in the world




Indian Pharmaceutical Industry Exports (\$ billion)




Growth Drivers

- Rising disposable income and increased healthcare awareness are driving demand for high-quality pharmaceutical products across all income segments
- India's large and aging population, along with growing prevalence of chronic and lifestyle-related diseases, is expanding pharmaceutical consumer base
- Increasing investments in research and development and growing base of clinical trials are enhancing India's innovation capabilities in drug development
- Government initiatives such as Production Linked Incentive scheme, Ayushman Bharat and Jan Aushadhi scheme are promoting domestic manufacturing and wider access to medicines

Global Pharmaceutical Market (Us \$ Billion)



Indian Pharmaceutical Market (Us \$ Billion)



CDMO Industry Overview

Global CDMO Industry

Role & Importance of CDMOs

- End-to-end services from drug development to commercial production, helping pharma firms cut costs, scale faster, and access advanced technologies

Key Market Drivers

- Rising demand for biologics, outsourcing by small/mid-sized firms, strategic partnerships, and growing R&D.

Market Trends

- Shift toward full-service, end-to-end CDMO models, Digitalization and sustainable manufacturing practices and M&A led consolidation

Challenges

- Strict FDA, EMA GMP regulations leading to higher costs and delays
- Fragmented market with strong competition from small & mid-sized players

Regional Insights

- **North America:** Largest market share (38.59% in 2024), supported by strong CDMO networks and high clinical trial activity
- **Asia-Pacific (including India):** Fastest growth due to cost advantages and rising R&D investments

Market Size & Growth Outlook

- Valued at **USD 220 billion in 2025**
- Expected to reach **USD 400 billion by 2034**
- Growing at a **CAGR of 7.4%**

Source : Fortune business insights,

Indian CDMO Industry

India's CDMO sector is set to double from USD 22.5 Billion to USD 44 Billion by 2029, capturing 4–5% of the global market and establishing India as a key force in the pharmaceutical and biopharmaceutical industries

Key Drivers of Growth

- India's proven strength in APIs and generics provides a solid foundation for rapid CDMO growth
- The sector is shifting from cost arbitrage to high-value services, including complex formulation development, biologics, peptides, and specialized chemicals
- India hosts the highest number of USFDA-approved manufacturing plants outside the U.S
- India's CDMO services offer ~20% lower costs than China, making the Country a highly attractive choice for global pharma companies
- Global pharma firms are shifting supply chains away from China, driving a 50% YoY surge in RFPs for Indian CDMOs in 2024

your text

Financial Overview



Management Comment



Mr. Vivek Ashok Kumar Patel
Promoter, Managing Director

“We are pleased to report a strong financial and operational performance for FY26, marked by robust revenue growth and continued expansion across key business areas. During the year, the Company achieved a total income of ₹89.63 crore, reflecting a growth of 56.21% YoY, while Profit After Tax increased by 42.30% YoY to ₹9.67 crore. The growth was primarily driven by volume expansion and an improved product mix, particularly in the Oral Liquid and Tablet categories, which continued to witness healthy demand across markets.

FY26 has been a year of strong operational progress and strategic execution for Accretion Pharmaceuticals Limited. We continued to witness robust demand momentum across our core export markets, supported by a healthy order book, expanding product portfolio, and increasing penetration in Africa, Latin America, and Southeast Asia.

During the year, we focused on scaling our CDMO capabilities and improving capacity utilization across key dosage forms, which has enabled us to deliver consistent revenue growth. While margins during the year were impacted by product mix changes, upfront investments in product registrations, and compliance-related costs, we remain confident of a gradual improvement in profitability as these investments begin to yield results and operating leverage improves.

Our export-led strategy continues to be a key growth driver, with ongoing efforts to transition towards higher-margin direct exports and expand into new geographies. With over 100 products under registration and multiple market approvals underway, we are well positioned to deepen our presence in existing regions while unlocking new opportunities.

Looking ahead, we remain focused on driving sustainable growth through enhanced capacity utilization, continued investments in product development and registrations, and strengthening our global partnerships. We are confident that our disciplined approach, strong execution capabilities, and expanding international footprint will enable us to deliver long-term value for all stakeholders.”


Thank you for your ongoing support and trust in Accretion Pharmaceuticals Limited.”

CSR Update

- Contributed ₹ 12,11,111 to the Lilavati Foundation towards the construction of its new building in Ahmedabad
- This contribution reflects the Company's commitment to supporting social infrastructure and community development initiatives, while reinforcing its focus on creating a positive and lasting impact beyond business operations
- Through this contribution, the Company aims to play a meaningful role in strengthening healthcare-related infrastructure and enabling better access to quality services for the community
- Accretion Pharmaceuticals Limited continues to believe that sustainable growth goes hand-in-hand with contributing positively to society and creating long-term value for all stakeholders



Responsible Manufacturing. Sustainable Future



In-house rooftop solar installation supporting clean energy consumption



Solar Power Utilization

In-house rooftop solar installation reduces grid dependence and lowers operational carbon footprint



Energy-Efficient Machinery

Modern manufacturing equipment designed for optimised energy consumption and improved operational efficiency



Optimized Logistics

Streamlined supply chain and distribution practices to minimise fuel use, emissions and transit-related impact

Half Yearly Financial Highlights

Particulars (Rs. in Crore)	H2 FY26	H2 FY25	YoY%	H1 FY26
Total Income from Operations	45.89	38.81	18.24%	43.74
Raw Materials	33.00	27.93		32.15
Employee Cost	2.43	2.13		2.06
Other Expenses	2.58	1.21		2.45
Total Expenditure	38.01	31.27	21.55%	36.67
EBITDA*	7.88	7.54	4.50%	7.07
EBITDA Margin* (%)	17.17%	19.43%	(226 bps)	16.17%
Other Income	0.08	0.08		0.11
Depreciation	0.81	0.41		0.40
Interest	0.48	0.74		0.37
Exceptional Item (Gain) / Loss	0.00	0.00		0.00
Profit Before Tax	6.67	6.47	3.13%	6.41
Tax	1.76	2.14		1.66
Profit After Tax	4.92	4.33	13.55%	4.75
Profit After Tax Margin%	10.71%	11.15%	(44 bps)	10.87%
EPS (In Rs.)	4.42	5.30	(16.60%)	4.61

* Excl. Other Income


Revenue in H2 FY26 stood at Rs. 45.89 crore, up 18.24% YoY, driven by volume expansion and product mix improvement

EBITDA grew 4.50% YoY to Rs. 7.88 crore with a 17.17% margin


PAT increased 13.55% YoY to Rs. 4.92 crore with a 10.71% margin

Financial Highlights - Annually


Revenue (Rs. Cr)




EBITDA* (Rs. Cr) / Margin (%)




PAT (Rs. Cr) / Margin (%)




5 Years CAGR (%)



Net Worth (Rs. Cr)



Capital Employed (Rs. Cr)



*EBITDA excluding Other Income

Annual Financial Highlights

Particulars (Rs. in Crore)	FY26	FY25	FY24	FY23	FY22
Total Income from Operations	89.63	57.38	33.67	29.38	22.29
Raw Materials	65.15	39.91	21.61	23.35	17.56
Employee Cost	4.49	3.67	2.62	2.47	1.96
Other Expenses	5.04	1.91	1.95	1.57	1.13
Total Expenditure	74.68	45.50	26.18	27.39	20.65
EBITDA*	14.95	11.88	7.49	1.99	1.64
EBITDA Margin* (%)	16.68%	20.71%	22.25%	6.78%	7.35%
Other Income	0.19	0.09	0.27	0.15	0.29
Depreciation	1.21	0.77	0.85	0.92	0.81
Interest	0.85	1.44	1.15	1.08	1.02
Exceptional Item (Gain) / Loss	0.00	0.00	0.00	0.00	0.00
Share of P/L of associates	0.00	0.00	0.00	0.00	0.00
Profit Before Tax	13.08	9.76	5.76	0.14	0.10
Tax	3.42	2.97	1.89	0.03	0.03
Profit After Tax	9.67	6.79	3.88	0.10	0.08
Profit After Tax Margin%	10.79%	11.84%	11.50%	0.35%	0.40%
EPS (In Rs.)	9.03	8.48	9.69	-	-

* Excl. Other Income

Balance Sheet Highlights





Rs. Crore

Liabilities	FY26	FY25	FY24	FY23	FY22
Shareholder's Funds	54.71	15.29	5.35	3.84	3.08
Share capital	11.12	8.17	4.00	3.84	3.08
Reserves & Surplus	43.59	7.12	1.35	0.00	0.00
Non-current liabilities	1.13	1.36	7.04	2.91	2.93
Long term borrowings	0.86	1.17	6.91	2.87	2.90
Defer Tax liabilities	0.27	0.19	0.02	0.00	0.00
Long term provision	0.00	0.00	0.10	0.04	0.03
Current liabilities	20.81	23.23	14.66	13.83	11.73
Short Term Borrowings	11.46	12.94	6.57	5.60	4.71
Trade Payables	5.77	7.59	6.58	7.85	6.74
Other Current liabilities	0.05	0.04	0.22	0.32	0.26
Short-term provisions	3.53	2.66	1.29	0.06	0.03
Total Equities & Liabilities	76.66	39.87	27.05	20.58	17.74

Rs. Crore


Assets	FY26	FY25	FY24	FY23	FY22
Non-current assets	16.06	6.33	5.46	6.05	5.86
Property, Plant & Equipment	13.21	6.09	5.27	6.01	5.84
Working Capital in progress	0.20	0.00	0.00	0.00	0.00
Long term loans & advances	0.08	0.08	0.13	0.04	0.03
Other Non Current Assets	2.57	0.16	0.05	0.00	0.00
Current assets	60.59	33.55	21.59	7.76	11.88
Inventories	28.37	20.61	14.48	7.76	6.93
Trade receivables	22.40	11.66	5.80	5.80	4.07
Cash & Cash equivalents	4.02	0.05	0.09	0.04	0.37
Short-term loans & Advances	5.54	1.10	1.21	0.92	0.50
Other Current Assets	0.26	0.12	0.00	0.00	0.00
Total Assets	76.66	39.87	27.05	20.58	17.74

Key Ratios




Working Capital Analysis (Days)


Inventory




Receivables



Payables



Net Working Capital



Way



Ahead



01.

Geographical Diversification

- Strengthening presence across Asia and Africa by moving from merchant exports to direct market engagement
- Driving growth through expanded product registrations and local distributors to deliver high-quality pharmaceuticals sustainably

02.

New Product Development

- Scaling existing products while launching innovative solutions across high-end and mid-segment markets
- Enriching product range to address evolving demand and strengthen leadership in high-impact pharmaceuticals

03.

Advancing Manufacturing Excellence

- Modernizing Ahmedabad plant with advanced equipment to boost efficiency, compliance, and capacity
- Strengthening competitiveness to meet rising demand and support international growth

04.

Strengthening Relationships And Expertise

- Empower teams with continuous training and feedback-driven improvements to enhance satisfaction and loyalty
- Leveraging manufacturing and marketing expertise to ensure quality offerings and build long-term, mutually beneficial partnerships

05.

Adding New Customer and increasing wallet share of existing customers

- Adding more customers by entering new geographies
- Increasing wallet share of existing customers by new product addition

Embedding sustainability, people and responsible governance into our operating model



Environmental Responsibility

- Focus on reducing environmental impact through process optimization and efficient manufacturing practices
- Continuous initiatives towards lowering carbon emissions and energy consumption
- ISO 14001:2015 certified environmental management systems
- Optimized water utilization and controlled waste management processes
- Use of modern manufacturing equipment for improved operational efficiency
- Controlled HVAC systems and closed-loop water distribution systems to support sustainable operations
- Emphasis on paperless documentation and digital process integration



Social Commitment

- Building a skilled and growth-oriented workforce
- Focus on employee safety, hygiene, and professional development
- Promoting ethical business conduct and inclusive work culture
- Enhancing healthcare accessibility through affordable and quality products
- Expanding global healthcare reach across 30+ countries



Towards a Low-Carbon Future

- Energy-efficient manufacturing infrastructure
- Process optimization to reduce resource consumption
- Reduction in operational carbon footprint
- Responsible waste handling and environmental compliance
- Sustainable infrastructure development initiatives
- Continuous focus on green manufacturing practices

Thank You

Company :	Investor Relations Advisors :
<p data-bbox="403 691 856 719">Accretion Pharmaceuticals Limited.</p> <p data-bbox="403 765 600 794">CS Roshni Shah</p> <p data-bbox="403 840 848 869">compliance@accretionpharma.com</p> <p data-bbox="403 989 751 1018">www.accretionpharma.com</p>	<p data-bbox="1001 691 1283 719">Adfactors PR Pvt. Ltd.</p> <p data-bbox="1001 765 1577 830">Mr. Rupesh Rege / Mr. Chaitanya Satwe/ Ms. Mousami Chavan</p> <p data-bbox="1001 840 1383 869">rupesh.rege@adfactorspr.com</p> <p data-bbox="1001 876 1434 905">chaitanya.satwe@adfactorspr.com</p> <p data-bbox="1001 912 1451 941">mousami.chavan@adfactorspr.com</p> <p data-bbox="1001 1061 1278 1090">www.adfactorspr.com</p>